title: Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele.
authors.forename: T
authors.initials: T
authors.lastname: Okamoto
authors.forename: M
authors.initials: M
authors.lastname: Okada
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Takatsuka
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: A
authors.initials: A
authors.lastname: Tamura
authors.forename: Y
authors.initials: Y
authors.lastname: Fujimora
authors.forename: Y
authors.initials: Y
authors.lastname: Takemoto
authors.forename: E
authors.initials: E
authors.lastname: Kakishita
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D006684:HLA-DR Antigens / Q000187:drug effects / Q000235:genetics*; D059811:HLA-DRB1 Chains; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D007166:Immunosuppressive Agents; D016572:Cyclosporine